AARP Rx Watchdog Report
Executive Summary
AARP's latest drug price study, issued Nov. 2, found prices rose 6.1% for nearly 200 of the most common brand name prescriptions during the 12 month period ending in June. The rate is slightly less than the 7.1% increase reported by AARP in 2004 (1"The Pink Sheet" April 18, 2005, p. 16). Products with the "sharpest" price increases over the first six months of 2005 included Sanofi-Aventis' Ambien 5 mg (14.4%) and Boehringer Ingelheim's Atrovent (18.6%). The Pharmaceutical Research & Manufacturers of America disputed the report, stating the Consumer Price Index price for prescription drugs increased only 3.4% for the same period...
AARP's latest drug price study, issued Nov. 2, found prices rose 6.1% for nearly 200 of the most common brand name prescriptions during the 12 month period ending in June. The rate is slightly less than the 7.1% increase reported by AARP in 2004 (1 (Also see "Price Increases For Branded Drugs Slower Since Medicare Drug Card – AARP" - Pink Sheet, 18 Apr, 2005.), p. 16). Products with the "sharpest" price increases over the first six months of 2005 included Sanofi-Aventis' Ambien 5 mg (14.4%) and Boehringer Ingelheim's Atrovent (18.6%). The Pharmaceutical Research & Manufacturers of America disputed the report, stating the Consumer Price Index price for prescription drugs increased only 3.4% for the same period.... |